Publications
2018
Bluestein BM, Morrish F, Graham DJ, Huang L, Hockenbery D, Gamble LJ. Analysis of the Myc-induced pancreatic β cell islet tumor microenvironment using imaging ToF-SIMS. Biointerphases. 2018; 13(3):06D402. PMCID: PMC6113053.
2017
Kern HB, Srinivasan S, Convertine AJ, Hockenbery D, Press OW, Stayton PS. Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Proapoptotic Peptides. Molecular pharmaceutics. 2017; 14(5):1450-1459. PMCID: PMC5823688.
2016
Bluestein BM, Morrish F, Graham DJ, Guenthoer J, Hockenbery D, Porter PL, Gamble LJ. An unsupervised MVA method to compare specific regions in human breast tumor tissue samples using ToF-SIMS. The Analyst. 2016; 141(6):1947-57. PMCID: PMC4783233.
Aguilar E, Marin de Mas I, Zodda E, Marin S, Morrish F, Selivanov V, Meca-Cortés Ó, Delowar H, Pons M, Izquierdo I, Celià-Terrassa T, de Atauri P, Centelles JJ, Hockenbery D, Thomson TM, Cascante M. Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program. Stem cells (Dayton, Ohio). 2016; 34(5):1163-76. PMCID: PMC4860823.
Margineantu DH, Hockenbery DM. Mitochondrial functions in stem cells. Current opinion in genetics & development. 2016; 38:110-117.
Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, Loghman-Adham M, Gelmont D, Storer B, Hansen JA, Deeg HJ. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016; 22(9):1596-1601.
Iwata TN, Ramírez JA, Tsang M, Park H, Margineantu DH, Hockenbery DM, Iritani BM. Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism. Journal of immunology, 2016; 197(6):2250-60. PMCID: PMC5009877.
Berger S, Procko E, Margineantu D, Lee EF, Shen BW, Zelter A, Silva DA, Chawla K, Herold MJ, Garnier JM, Johnson R, MacCoss MJ, Lessene G, Davis TN, Stayton PS, Stoddard BL, Fairlie WD, Hockenbery DM, Baker D. Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer. eLife. 2016; 5. PMCID: PMC5127641.
2015
Reyes NL, Banks GB, Tsang M, Margineantu D, Gu H, Djukovic D, Chan J, Torres M, Liggitt HD, Hirenallur-S DK, Hockenbery DM, Raftery D, Iritani BM. Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112(2):424-9. PMCID: PMC4299192.
Evans AT, Loeb KR, Shulman HM, Hassan S, Qiu WC, Hockenbery DM, Ioannou GN, Chauncey TR, Gretch DR, McDonald GB. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. The American journal of surgical pathology. 2015; 39(2):212-20.
Gamble LJ, Graham DJ, Bluestein B, Whitehead NP, Hockenbery D, Morrish F, Porter P. ToF-SIMS of tissues: "lessons learned" from mice and women. Biointerphases. 2015; 10(1):019008. PMCID: PMC4327923.
Berguig GY, Convertine AJ, Frayo S, Kern HB, Procko E, Roy D, Srinivasan S, Margineantu DH, Booth G, Palanca-Wessels MC, Baker D, Hockenbery D, Press OW, Stayton PS. Intracellular delivery system for antibody-Peptide drug conjugates. Molecular therapy : the journal of the American Society of Gene Therapy. 2015; 23(5):907-917. PMCID: PMC4427876.
Robinson MA, Graham DJ, Morrish F, Hockenbery D, Gamble LJ. Lipid analysis of eight human breast cancer cell lines with ToF-SIMS. Biointerphases. 2015; 11(2):02A303. PMCID: PMC4552699.
Sperber H, Mathieu J, Wang Y, Ferreccio A, Hesson J, Xu Z, Fischer KA, Devi A, Detraux D, Gu H, Battle SL, Showalter M, Valensisi C, Bielas JH, Ericson NG, Margaretha L, Robitaille AM, Margineantu D, Fiehn O, Hockenbery D, Blau CA, Raftery D, Margolin AA, Hawkins RD, Moon RT, Ware CB, Ruohola-Baker H. The metabolome regulates the epigenetic landscape during naive-to-primed human embryonic stem cell transition. Nature cell biology. 2015; 17(12):1523-35. PMCID: PMC4662931.
2014
Hockenbery DM. Forecast: rough seas for leukemia. Cancer discovery. 4(3):278-9. 2014. PMID: 24596202.
Morrish F., Hockenbery D. MYC and mitochondrial biogenesis. Cold Spring Harbor perspectives in Medicine. 4(5). 2014. PMCID: PMC3996374.
Procko E, Berguig GY, Shen BW, Song Y, Frayo S, Convertine AJ, Margineantu D, Booth G, Correia BE, Cheng Y, Schief WR, Hockenbery DM, Press OW, Stoddard BL, Stayton PS, Baker D. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein apoptosis in infected cells. 157(7):1644-1656. 2014. PMCID: PMC4079535.
Marcondes AM, Karoopongse E, Lesnikova M, Margineantu D, Welte T, Dianrello CA, Hockenbery D, Janciauskiene S, Deeg HJ. α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood. 124(18):2881-91. 2014 PMCID: PMC4215316.
2013
Suchorolski MT, Paulson TG, Sanchez CA, Hockenbery D, Reid BJ. Warburg and Crabtree effects in premalignant Barrett’s esophagus cell lines with active mitochondria. PIoS one. 8(2):e56884. 2013. PMCID: PMC3584058.
2012
Park H, Staehling K, Tsang M, Appleby MW, Brunkow ME, Margineantu D, Hockenbery DM, Habib T, Liggitt HD, Carlson G, Iritani BM. Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development. Immunity. 36(5):769-81, 2012. PMCID: PMC3361584
2011
Jung SR, Kuok IT, Couron D, Rizzo N, Margineantu DH, Hockenbery DM, Kim F, Sweet IR. Reduced cytochrome C is an essential regulator of sustained insulin secretion by pancreatic islets. J Biol Chem. 286(20):17422-34, 2011. PMCID: PMC3093816.
Lord JD, Hackman RC, Gooley TA, Wood BL, Moklebust AC, Hockenbery DM, Steinbach G, Ziegler SF, McDonald GB. Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease. Biol Blood Marrow Transplant 17(4):486-96, 2011. PMCID: PMC3026868
May D, Pan S, Crispin DA, Lai K, Bronner MP, Hogan J, Hockenbery DM, McIntosh M, Brentnall TA, Chen R. Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics. J Proteome Res. 10(1):200-9, 2011. PMCID: PMC3017661
2010
Morrish F, Noonan J, Perez-Olsen C, Gafken PR, Fitzgibbon M, Kelleher J, VanGilst M, Hockenbery D. Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J Biol Chem. 285(47):36267-74, 2010. PMCID: PMC2978554
Delgado T, Carroll PA, Punjabi AS, Margineantu D, Hockenbery DM, Lagunoff M. Induction of the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently infected endothelial cells. Proc Natl Acad Sci USA 107(23):10696-701, 2010. PMCID: PMC2890792
Hockenbery DM. Targeting Mitochondria for cancer therapy. Environ Mol Mutagen. 51(5):476-89, 2010. Review.
2009
Brinkkoetter PT, Olivier P, Wu JS, Henderson S, Krofft RD, Pippin JW, Hockenbery D, Roberts JM, Shankland SJ. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest [epub ahead of print] doi: 10.1172/JCI37978, 2009. PMCID: PMC2752065
Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, Tateya S, Handa S, Schwartz MW, Kim F. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 29(9):1370-5, 2009 PMCID: PMC2775080
Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 29(27):2485-91, 2009. PMCID: PMC2779836
Sweet IR, Gilbert M, Maloney E, Hockenbery DM, Schwartz MW, Kim F. Endothelial inflammation induced by excess glucose is associated with cytosolic glucose 6-phosphate but not increased mitochondrial respiration. Diabetologia 52(5):921-31, 2009. PMCID: PMC2741088.
Susnow NJ, Hockenbery DM. Bak to basics of colonocyte renewal. Gastroenterology 136(3):763-6, 2009. Editorial.
Susnow N, Zeng J, Margineantu D, Hockenbery DM. Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol. 19(1):42-9, 2009. Review.
2008
Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp Hematol. 36(12):1660-72, 2008. PMCID: PMC2645417
Morrish F, Neretti N, Sedivy JM, Hockenbery DM. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle. 7(8):1054-66, 2008. PMCID: PMC2518168
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer. 47(1):8-20, 2008.
2007
Margineantu DH, Emerson CB, Diaz D, Hockenbery DM. Hsp90 inhibition decreases mitochondrial protein turnover. PLoS One. 2(10):e1066, 2007. PMCID: PMC2031825
Hockenbery DM. Oral beclomethasone dipropionate in gastrointestinal graft-versus-host disease. Exper Rev Clin Immunol. 3(5):695-700, 2007. Review.
Schwartz PS, Manion MK, Emerson DB, Fry JS, Schultz CM, Sweet IR, Hockenbery DM. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol Cancer Ther. 6(7):2073-80, 2007.
Phelps RA, Gingras H, Hockenbery DM. Loss of FANCC function is associated with failure to inhibit late firing replication orgins after DNA cross-linking. Exp Cell Res. 313(11):2283-92, 2007.
Ying SX, Seal S, Abbassi N, Hockenbery DM, Kiem HP, Li X, Pagel JM, Gopal AK, Deeg HJ. Differential effect of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk. Lymphoma. 48(5):1003-14, 2007.
Schwartz PS, Hockenbery DM. Targeted therapies for epithelial cancers: in vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA. Cancer Biol Ther. 6(3):465-6, 2007. Review.
Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109(10):4557-63, 2007.
2006
Manion MK, Fry J, Schwartz PS, Hockenbery DM. Small-molecule inhibitors of Bcl-2. Curr Opin Investig Drugs. 7(12):1077-84, 2006. Review.
Hockenbery DM. MMPs in unusual places. Am J Pathol. 169(4):1101-3, 2006. Review.
Schwartz PS, Hockenbery DM. Bcl-2-related survival proteins. Cell Death Differ. 13(8):1250-5, 2006. Review.
Morrish F, Buroker NE, Ge M, Ning XH, Lopez-Guisa J, Hockenbery D, Portman MA. Thyroid hormone receptor isoforms localize to cardiac mitochondrial matrix with potential for binding to receptor elements on mtDNA. Mitchondrion. 6(3):143-8, 2006.
Holmberg L, Kikuchi K, Gooley TA, Adams KM, Hockenbery DM, Flowers ME, Schoch HG, Bensinger W, McDonald GB. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 12(2):226-34, 2006.
O'Neill JW, Manion MK, Maguire B, Hockenbery DM. BCL-XL dimerization by three-dimensional domain swapping. J Mol Biol. 356(2):367-81, 2006.
Selinger RR, McDonald GB, Hockenbery DM, Steinbach G, Kimmey MB. Efficacy of neodymium: YAG laswer therapy for gastric antral vascular ectasia (GAVE) following hematopoietic cell transplant. Bone Marrow Transplant. 37(2):191-7, 2006.
2005
Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res. 11(13):4857-66, 2005.
Wang H, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, Hill DL. Preclinical parmacology of 2-methoxyantimycin A compounds as novel antitrumor agents. Cancer Chemother Pharmacol. 56(3):291-8, 2005.
Ho HK, Hu ZH, Tzung SP, Hockenbery DM, Fausto N, Nelson SD, Bruschi SA. BCL-xL overexpression effectively protects against tetrafluoroethylsystiene-induced intramitochondrial damage and cell death. Biochem Parmacol. 69(1):147-57, 2005.
Hockenbery DM, Nunez G. A death in the family: Stanley J Korsmeyer (1950-2005). Cell Death Differ 12:691-2, 2005.
2004
O'Neill J, Manion M, Schwartz P, Hockenbery DM. Promises and challenges of targeting BCL-2 anti-apoptotic proteins for cancer therapy. Biochim Biophys Acta. 1705(1):43-51, 2004. Review.
Perry ME, Dang CV, Hockenbery D, Moll U. Highlights of the National Cancer Institute Workshop on mitochondrial function and cancer. Cancer Res. 64(20):7640-4, 2004.
Hockenbery D. Breaking down trumor defenses. Chem Biol. 11(4):417-8, 2004. Review.
Erxleben HA, Manion MK, Hockenbery DM, Scampavia L, Ruzicka J. A novel approach for monitoring extracellular acidification rates: based on bead injection spectrophotometry and the lab-on-valve system. Analyst. 129(3):205-12, 2004.
Lesnikov VA, Lesnikova MP, Shulman HM, Wilson HM, Hockenbery DM, Kocher M, Pierpaoli W, Deeg HJ. Prevention of Fas-mediated hepatic failure by tranferrin. Lab Invest. 84(3):342-52, 2004.
Manon MK, O'Neill JW, Giedt CD, Kim KM, Zhang KY, Hockenbery DM. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem. 279(3):2159-65, 2004.
2003
Wright ME, Eng J, Sherman J, Hockenbery DM, Nelson PS, Galitski T, Aebersold R. Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol. 5(1):R4, 2003.
Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther. 2(4 Suppl 1):S105-14, 2003. Review.
Pinto-Marques P, Hockenbery DM, Hackman RC, Tapper D, McDonald GB. Successful medical treatment of intestinal ulceration caused by Rhizopus microsporus. Bone Marrow Transplant. 32(7):739-40, 2003.
O'Neill JW, Hockenbery DM. Bcl-2-related proteins as drug targets. Curr Med Chem. 10(16):1553-62, 2003. Review.
Haughn L, Hawley RG, Morrison DK, von Boehmer H, Hockenbery DM. BCL-2 and BCL-XL restrict lineage choice during hematopoietc differentiation. J Biol Chem. 278(27):25158-65, 2003.
Morrish F, Hockenbery D. Myc's mastery of mitochondrial mischief. Cell Cycle. 2(1):11-3, 2003. Review.
Hockenbery DM. Nailing down a link between tuberin and renal cysts. Am J Pathol. 162(2):369-71, 2003. Review.
Morrish F, Giedt C, Hockenbery D. c-MYC apoptotic function is mediated by NRF-1 target genes. Genes Dev. 17(2):240-55, 2003.
Hockenbery DM. Making sense of Bcl-2 family of apoptotic regulators. Genetics of Apoptosis, BIOS Scientific Publishers, Oxford, 2003.
2002
Hockenbery DM, Giedt CD, O'Neill JW, Manion MK, Banker DE. Mitochondria and apoptosis: new therapeutic targets. Adv Cancer Res. 85:203-42, 2002. Review.
Hockenbery DM. A mitochondrial Achilles' heel in cancer? Cancer Cell. 2(1):1-2, 2002. Review.
2001
Seewaldt VL, Mrozek K, Sigle R, Dietze EC, Heine K, Hockenbery DM, Hobbs KB, Caldwell LE. Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis. J Cell Biol. 155(3):471-86, 2011.
Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, Zhang KY. Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry. 40(16):4911-22, 2001.
Schwartz JM, Wolford JL, Thornquist MD, Hockenbery DM, Murakami CS, Drennan F, Hinds M, Strasser SI, Lopez-Cubero SO, Brar HS, Ko CW, Saunders MD, Okolo CN, McDonald GB. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol. 96(2):385-93, 2001.
Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmberberg J, Zhang KY, Hockenbery DM. Antimycin A Mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol. 3(2):183-91, 2001.
2000
Wright ME, Han DK, Hockenbery DM. Caspase-3 and inhibitor of apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian cells. FEBS Lett. 481(1):13-8, 2000.
Welters CF, Piersma FE, Hockenbery DM, Heineman E. The role of apoptosis during intestinal adaptation after small bowel resection. J Pediatr Surg. 35(1):20-4, 2000.
Mancini M, Camillleri-Broet S, Anderson B, Hockenbery DM. Proliferative mitochondrial dysfunction and poptosis. In: Mattson MP, Estus S & Rangnekar V, eds. Advances In Cell Aging and Gerontology, Vol 5 Programmed Cell Death: Cellular and Molecular Mechanisms. Elsevier Science Netherland, 2000.
1999
Mostafapour SP, Hockenbery DM, Rubel EW. Life and death in otolaryngology: mechanisms of apoptosis and its role in the pathology and treatment of disease. Arch Otolaryngol Head Neck Surg. 125(7):729-37, 1999. Review.
Wright ME, Han DK, Carter L, Fields S, Schwartz SM, Hockenbery DM. Caspase-3 inhibits growth in Saccharomyces cervisiae without causing cell death. FEBS Lett. 446(1):9-14, 1999.
1998
Tzung SP, Hackman RC, Hockenbery DM, Bensinger W, Schiffman K, McDonald GB. Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 4(1):43-8, 1998.
Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO. Bcl-2 slows in vitro breast cancer growth despite ins antiapoptotic effect. J Surg Res. 76(1):22-6, 1998.
McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, Murakami C, Levine DS. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trail. Gastroenterology. 115(1):28-35, 1998.
Mancini M, Sedghinasab M, Knowlton K, Tam A, Hockenbery D, Anderson BO. Flow cytometric measurement of mtochondrial mass and function: a novel method for assessing chemoresistance. Ann Surg Oncol. 5(3):287-95, 1998.
Camilleri-Broet S, Vanderwerff H, Caldwell E, Hockenbery D. Distinct alterations in mitochondrial mass and function characterize different models of apoptosis. Exp Cell Res. 239(2):277-92, 1998.
1997
Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol. 138(2):449-9, 1997.
Tzung SP, Fausto N, Hockenbery DM. Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am J Pathol. 150(6):1985-95, 1997.
Robertson KA, Hill DP, Xu Y, Liu L, Van Epps S, Hockenbery DM, Park JR, Wilson TM, Kelley MR. Down-regulation of apurinic/apyrimidinc endonuclease expression is associated with the induction of apoptosis in differentiating myeloid leukemia cells. Cell Growth Differ. 8(4):443-9, 1997.
Hirose K, Hockenbery DM, Rubel EW. Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. Hear Res. 104(1-2):1-14, 1997.
1996
Karasawas N, Erukulla RK, Bittman R, Lockshin R, Hockenbery D, Zakeri Z. BCL-2 suppresses ceramide-induced cell killing. Cell Death Differ. 3(1):149-51, 1996.
Park JR, Hockenbery DM. Bcl-2, a novel regulator of apoptosis. J Cell Biochem. 60:12-17, 1996. Review.
1995
Baehr PH, Levine DS, Bouvier ME, Hockenbery DM, Gooley TA, Stern JG, Martin PJ, McDonald GB. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation. 60(11):1231-8, 1995.
Hong DS, Beckham C, Huss R, Lee JW, Hockenbery D, Ledbetter JA, Deeg HJ. Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-germ marrow cultures involves apoptosis and is prevented by c-kit ligand. Blood. 86(9):3341-52, 1995.
Park JR, Bernstein ID, Hockenbery DM. Primitive human hematpoietic precursors express Bcl-x but not Bcl-2. Blood. 86(3):868-76, 1995.
Hockenbery DM. bcl-2, a novel regulator of cell death. Bioessays. 17(7):631-8, 1995. Review.
Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, Herman B. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem. 57(3):509-21, 1995.
Hockenbery DM. Defining apoptosis. Am. J. Path. 146:16-19, 1995. Review.
1994
Park JR, Robertson K, Hickstein DD, Tsai S, Hockenbery DM, Collins SJ. Dysregulated bcl-2 expression inhibits apoptosis but not differentiation of retinoic acid-induced HL-60 granulocytes. Blood. 84(2):440-5, 1994.
Hockenbery DM. bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl. 18:51-5, 1994. Review.
1993
Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75(2):241-51, 1993.
Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrojen mustard and camptothecin induced apoptosis. Cancer Res. 53(8):1853-61, 1993.
Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin. in Immunol. 4: 413-420, 1993.
1992
Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89(16):7742-6, 1992.
Clouse RE, Aplers DH, Hockenbery DM, DeSchryver-Kecskemeti K. Pericrypt eosinophilic enterocolitis and chronic diarrhea. Gastroenterology. 103(1):168-76, 1992.
1991
Sentman CL, SHutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67(5):879-88, 1991.
Nunez G, Hockenbery D, McDonnell TJ, Sorensen CM, Korsmeyers SJ. Bcl-2 maintains B cell memory. Nature. 353(6339):71-3, 1991.
Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88(16):6961-5, 1991.
Zutter M, Hockenbery D, Silverman GA, Korsmeyer SJ. Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood. 78(4):1062-8, 1991.
1990
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348(6299):334-36, 1990.
Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 144(9):3602-10, 1990.
Korsmeyer SJ, McDonnell TJ, Nunez G, Hockenbery D, Young R. Bcl-2: B cell life, death, and neoplasia. Curr Top Microbiol Immunol. 166:203-7, 1990.
1983
Lock DR, Hockenbery DM, Cunningham J, Hakm KS, Kantor O, Schonfeld G. Apolipoprotein B subspecies in chylomicrons isolated from a patient with chyluria. Am J Med. 75:360-63, 1983.
1978
Colello GD, Hockenbery DM, Bosmann HB, Fuchs S, Folkers K. Competitive inhibition of benzodiazepine binding by fractions from porcine brain. Proc Nalt Acad Sci USA 75:6319-23, 1978.
Chapter Proceedings
Hockenbery DM, Danial NN: Cell Death. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P. Hematology: Basic Principles and Practice, 5h ed. Philadelphia: Elsevier 2009.
Hockenbery DM: Principles of cell killing by biologic agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer, 2nd ed. Philadelphia: J.B. Lippincott, 1995.
Hockenbery DM: Applications of new technology in tissue examination. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of Gastroenterology, 2nd ed. Philadelphia: J.B. Lippincott, 1995.
Hockenbery DM: The bcl-2 gene: a regulator of programmed cell death. In: Mihich E, Schimke RT, eds. Apoptosis. New York: Plenum Press, 1994.
Korsmeyer SJ, McDonnell TJ, Nunez G, Hockenbery D, Young R: Bcl-2: B cell life, death and neoplasia. In: Current Topics in Microbiology and Immunology. Mechanisms of B Cell Neoplasia Conference, Bethesda, MD. Springer-Verlag, pp. 203-207, 1990.
Korsmeyer SJ, McDonnell TJ, Nunez G, Jaeger U, Hockenbery D, Young R: Role of the Bcl-2 proto-oncogene in neoplasia. In: Progress in Immunology, 7th Int'l Congress, Berlin. Springer-Verlag, Heidelberg, pp. 489-493, 1989.
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.